GREETINGS!

What a month! The insane waste of human life represented by the invasion of Ukraine is tragic on so many fronts. Second to the loss of life by war violence, is the loss of life due to preventable infectious diseases. Indeed, Ukraine represented one of the strongest partners in research on new TB treatment regimens. We have another hurdle to overcome to #EndTB, so let us spare some prayers, take a deep breath, and dive in together!

DC UPDATE

2022 Global Fund Replenishment Conference – An early win!

The United States will be hosting the 2022 Global Fund Replenishment Conference for the first time! Read about the investment case from the Global Fund and from the Friends of the Global Fight. Late in March the Biden Administration announced a pledge of $6 billion over 3 years. Please consider sending a thank you note to the White House and then calling your Members of Congress, so they follow through on that pledge and appropriate the full $2 billion for FY23.

Contact your Senators and Representatives!

There are lots of #TBElimination reasons to contact your Members of Congress. Please ask them to support the following funding levels in fiscal year 2023 appropriations bills:

$225 million for CDC’s TB program in FY2023 through Labor-HHS Appropriations.

Every US state reports cases of TB annually, many states report deaths from TB, and there are up to 13 million people in the U.S. with latent TB infection. In the absence of a targeted prevention program, these individuals represent the reservoir of future active TB cases.

$21 million in dedicated funding for CDC’s Division of Global HIV and TB.

CDC’s mandate is to protect Americans from public health threats at home and abroad. Yet its work on global TB is underfunded. Increased funding would allow the agency to address the nexus between global TB epidemics and the incidence of TB in the U.S. by strengthening TB elimination programs especially in countries contributing to the TB burden in the U.S. such as Mexico, Vietnam, and the Philippines.

Include TB in the CDMRP Peer Reviewed Medical Research Program in Fiscal Year 2023.

TB was first included on PRMRP the eligible disease list in FY 2016 but has been excluded ever since. During the time it was included, over $23 million was awarded to TB research and development institutions around the US. This program is a critical part of the US government’s TB research infrastructure and we urge you to ensure its inclusion on the list of eligible diseases again in FY 2023.
$1 billion for bilateral TB efforts in FY2023 State and Foreign Ops Appropriations.

USAID’s TB program provides technical assistance to 23 of the world’s most highly burdened countries, supports research and development and the Global Drug Facility. Additional funding is needed for USAID’s TB program to help countries adapt and restore TB programs, support the development of new TB diagnostic, treatment, and prevention tools, and prevent a dangerous reversal of progress against TB.

Finally...

A chance to Co-sponsor the Comprehensive TB Elimination Act of 2021

The Comprehensive TB Elimination Act of 2021 has now been reintroduced in both the Senate and in the House of Representatives. This reauthorizing bill is meant to fund domestic TB programs and focus TB elimination and research resources on priority populations in the US. Please read more about the legislature here and join the effort to gain cosponsors for the bill by contacting your senators and representatives. A sample script and instructions can be found on our website.

ANNOUNCEMENTS

NEW DATA: COVID-19 likely had a substantial effect on U.S. TB disease trends

COVID-19 has likely had a substantial effect on U.S. TB disease trends

NEW Think, Test, Treat TB Communications Campaign

CDC has launched a new communications campaign to raise awareness of latent TB infection. The Think, Test, Treat TB campaign aims to reach people most at risk for latent TB infection and their healthcare providers to encourage TB testing and treatment. The Think, Test, Treat TB website includes resources in multiple languages and a partner toolkit with communication materials.
CDC Announces 2022 U.S. TB Elimination Champions

As part of World TB Day observance activities, CDC announced 8 U.S. TB Elimination Champions. These Champions adapted TB prevention and control activities to the changing healthcare landscape and ensured equitable access to TB services. We are particularly proud of our Coordinating Board members Joe Lee and Ed Zuroweste who are key members of the TB Elimination Alliance, one of this year's Champions!

HIGHLIGHTED TB REPORTS/UPDATES

- Worrying lack of funding for tuberculosis
- The History of Tuberculosis Holds Lessons For Modern Day Public Health
- Media Statement: Effect of COVID-19 on Tuberculosis in the U.S.
- MSF responds to updated WHO guidelines for tuberculosis in children
- CROI 2022 TB Round Up
- March 24, 2022 – COVID-19 likely had a substantial effect on U.S. TB disease trends

Read more reports and updates on our website page ‘From TB Wire’!

TB IN THE NEWS

- Letter: Bill seeking to end tuberculosis supported
- CDC recommends 4-month regimen for drug-susceptible TB
- Did COVID-19 Hide or Reduce Tuberculosis Cases?
- World Tuberculosis Day Re-Energizes After COVID-19 Pandemic
- TAG: CROI 2022 TB Round Up
- Why coronavirus lockdown could see 6.3 million more people get tuberculosis

War in Ukraine:

- Ukraine’s ‘Model’ TB Programme Destroyed by War, as Global TB Response Faces ‘Disastrous’ Funds Shortfall
- Ukraine’s tuberculosis progress ‘stopped in one day’
- Russia’s invasion of Ukraine poses a threat to the control of drug-resistant TB in Europe and the world

Read lots more TB news on our website page ‘From TB Wire’!

TB RESOURCES

WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents

- Operational handbook
- Information sheet
New CDC Guidance for a 4-month TB Treatment Regimen

On February 24, 2022, CDC published new interim guidance in the Morbidity and Mortality Weekly Report for a 4-month treatment regimen to treat drug-susceptible TB disease that is effective as the standard 6-month regimen for TB treatment. CDC has resources on the 4-month rifapentine-moxifloxacin regimen including a Frequently Asked Questions (FAQ) webpage.

Find more TB resources on our website page ‘TB Resources’!

JOURNAL ARTICLES

- Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
- Telehealth Reduces Missed Appointments in Pediatric Patients with Tuberculosis Infection
- Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia
- Detecting Tuberculosis-Consistent Findings in Lateral Chest X-Rays Using an Ensemble of CNNs and Vision Transformers
- An All-Oral 6-Month Regimen for Multidrug-Resistant TB (the NExT Study): A Multicenter, Randomized Controlled Trial
- Reactivation of Tuberculosis in the Setting of COVID-19 Infection

Discover many more peer-reviewed articles on our website page ‘Peer-Reviewed Publications’!

COURSES/WORKSHOPS

The Union: Programmatic and Clinical Management of Drug-Resistant Tuberculosis

EVENTS, MEETINGS, & CONFERENCES

April 8th, 2022 – What’s New - Finding the New Normal in Family Planning, Opioids, TB, Mental Health, HIV, and STIs Virtual Conference

April 22nd, 2022 – What’s New - Finding the New Normal in Family Planning, Opioids, TB, Mental Health, HIV, and STIs Virtual Conference
May 13th-18th, 2022 – ATS 2022

May 23rd-26th, 2022 – NTCA 2022 National TB Conference - TB Elimination: Back in Focus

November 8th-11th – World Conference on Lung Health 2022 – Combating Pandemics: Today & Tomorrow

Stop TB USA: Where we unite to #EndTB!

Stop TB USA
stopbusa.org
leadership@stopbusa.org
1150 18th St NW Suite 300, Washington DC 20036-3803, US